Here is some fairly recent news that I didnt see posted.
SPECTRAL DIAGNOSTICS INC. APPOINTS JOSEPH P. LAURINO,
Ph.D., DIRECTOR OF SCIENTIFIC OPERATIONS AND MEMBER OF
SPECTRAL'S EXECUTIVE TEAM
Dr. Laurino to direct Spectral's Scientific and Clinical Programs which
support the Company's Commercial Development and Production of Today's
and Tomorrow's Cardiac Diagnostics.
TORONTO, July 7 /CNW/ - Spectral Diagnostics Inc. (TSE-SDI;
NASDAQ-DIAGF), developers of the Cardiac STATus(TM) line of rapid format
cardiac diagnostic test kits, reported today that Joseph P. Laurino, Ph.D. has
joined its executive ranks in the position of Director of Scientific
Operations. Prior to joining Spectral, Dr, Laurino had been Director of
Chemistry and Toxicology at the Memorial Hospital of Rhode Island and an
Assistant Professor of Pathology and Laboratory Medicine at Brown University.
Dr. Laurino has also had management experience in the biotechnology industry
most recently as Senior Vice President of Research and Development at American
Biogenetic Sciences, Inc., and earlier with Roche Diagnostic Systems and Bayer
(Technicon) Diagnostics.
In announcing the appointment, Douglas C. Ball, Chairman and CEO said,
``With his background in scientific and commercial matters directly relating
to cardiac diagnostics, Dr. Laurino is well positioned to ensure that our
scientific and clinical programs are executed in a manner that is efficient,
focused and in support of customer and market demands in the area of existing
and new point of care cardiac diagnostics.''
Continuing Mr. Ball added, ``As we build our base of customers through
Spectral's sales and marketing organization in North America and our
distribution network in much of Europe, the planning and management of the
scientific and clinical operations under Dr. Laurino's direction will take on
ever increasing importance. We are committed to ensuring that our scientific
and clinical developments are of the highest standard required by our
customers and marketing partners alike.''
Dr. Laurino received his undergraduate degree at Georgetown University,
Washington, D.C. in 1980 and Ph.D. from the University of Virginia,
Charlottesville, Virginia in 1985. His postgraduate training included the
National Institutes of Health Postdoctoral Research Fellow, Department of
Pathology and Laboratory Medicine, Washington University School of Medicine,
St. Louis, Missouri; 1985-1986. Relevant to Spectral's business, Dr. Laurino
has published in the field of biochemical markers of cardiac disease.
Located in Canada, the United States and Europe, Spectral's scientists,
sales and marketing organizations and other professionals are focused on the
development, manufacturing and commercialization of its Cardiac STATus(TM)
line of diagnostic panel tests including the CK-MB/Myoglobin Panel Test, the
Troponin I Panel Test and the patented Cardiac Panel(TM). Spectral's common
shares are listed on The Toronto Stock Exchange (symbol SDI) and the NASDAQ -
NMS - Exchange (symbol DIAGF).
The matters set forth in this press release are forward-looking
statements within the meaning of the ``safe harbor'' provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
are subject to risks and uncertainties, that may cause actual results to
differ materially. These risks are detailed from time to time in the
Company's periodic reports filed with the Securities and Exchange Commission
including the Company's Annual Report, Quarterly Reports and other periodic
filings. These forward-looking statements speak only as of the date hereof.
The Company disclaims any intent or obligation to update these forward-looking
statements.
|
